ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The British drug services firm Sterling Pharma Solutions has formed a partnership with ADC Biotechnology, a UK specialist in making antibody-drug conjugates (ADCs), in which Sterling will combine its high-potency small-molecule expertise with ADC’s conjugation technology. Sterling has invested an undisclosed sum in ADC and says it plans to buy the firm early next year. The pact follows Sterling’s acquisition of Alcami’s pharmaceutical chemical plant in Wisconsin earlier this year and a CiVentiChem plant in North Carolina last year.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X